Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Launched by CELLSIGHT TECHNOLOGIES, INC. · Oct 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a special imaging technique called [18F]-FARAG PET can help doctors understand how patients with advanced non-small cell lung cancer (NSCLC) respond to a type of treatment known as checkpoint inhibitor therapy (CkIT). The goal is to see if changes in the PET scan results can show how the cancer is responding to treatment. Participants in this study will have scans done before they start the therapy and again while they are receiving it. They will be followed for up to 12 months to monitor their health and the effects of the treatment.

To be eligible for this trial, participants must have a confirmed diagnosis of advanced NSCLC and plan to start immunotherapy, either alone or in combination with other treatments. They should also have measurable cancer and a good enough health status to participate. Unfortunately, individuals with serious health issues, pregnant or nursing women, and those with severe claustrophobia cannot take part in this study. Participants will not be kept in the dark about any part of the study, and all care providers will be aware of the treatment being given. This trial is currently enrolling patients at the University of Iowa.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease.
• • 2. Measurable disease.
• • 3. ECOG performance status of 0, 1 or 2.
• • 4. Subjects are willing to be followed at the University of Iowa.
• Exclusion Criteria:
• • 1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
• • 2. Pregnant women or nursing mothers.
• • 3. Patients with severe claustrophobia.